NATCO Pharma Ltd.

NSE: NATCOPHARM · Healthcare

₹807.00+1.31%06 Nov 2026

Ask the data

Instant answers about NATCO Pharma Ltd. — computed from its filings, no language model

Market cap₹14,445 cr

Current price₹807.00

High / Low₹1,206 / ₹782

P/E12.6

P/B1.57

Book value₹515.1

ROE12.4%

ROCE11.6%

Debt / equity0.08

Dividend yield0.62%

EPS (TTM)₹63.93

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	2,202	2,094	1,915	2,052	1,945	2,707	3,999	4,430	4,078
EBITDA	928	795	583	606	264	936	1,751	2,196	1,436
Operating margin	42.2%	37.9%	30.4%	29.5%	13.5%	34.6%	43.8%	49.6%	35.2%
Interest	15	19	22	13	18	14	19	24	37
Depreciation	66	81	100	117	143	164	187	235	207
Profit before tax	887	825	569	580	202	862	1,674	2,291	1,491
Tax	192	182	111	137	32	147	285	408	119
Net profit	696	644	461	441	170	715	1,388	1,885	1,418
EPS ₹	39.26	34.98	25.33	24.20	9.32	39.18	77.34	105.26	79.20
Operating cash flow	—	—	—	—	46	849	1,212	1,697	1,768
Capex	—	—	—	—	243	206	359	512	391
Dividend paid	—	—	—	—	82	100	171	108	90
Total assets	3,715	4,303	4,588	4,792	5,109	5,657	6,906	8,631	11,074
Equity	3,072	3,489	3,774	4,122	4,264	4,874	5,853	7,607	9,221

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	768	539	544	557	456	492	486	482	455	563	802	355	331	410	377	560	597	885	432	492	898	1,140	1,031	759	1,068	1,363	1,371	475	1,221	1,329	1,363	647	739	735
Operating profit	383	218	220	208	148	191	134	129	128	171	276	82	76	110	70	102	-19	395	95	106	339	528	458	268	497	805	804	39	548	571	579	159	128	186
Operating margin	49.9%	40.4%	40.6%	37.4%	32.5%	38.9%	27.7%	26.7%	28.2%	30.4%	34.5%	23.2%	23.0%	26.8%	18.7%	18.2%	-3.1%	44.7%	22.1%	21.5%	37.8%	46.3%	44.4%	35.3%	46.6%	59.1%	58.7%	8.2%	44.9%	43.0%	42.5%	24.5%	17.3%	25.4%
Other income	20	36	40	23	31	21	33	31	22	19	26	31	28	17	38	30	14	34	20	21	29	20	29	37	42	48	64	176	66	62	100	58	78	59
Interest	3	3	5	6	5	6	6	5	4	4	3	3	4	2	4	5	7	4	4	4	3	4	4	5	6	5	4	4	10	3	13	10	11	13
Depreciation	18	18	20	21	22	22	22	25	30	28	29	30	30	34	35	36	38	40	42	42	41	44	44	44	56	44	46	47	98	58	52	46	50	47
Profit before tax	382	232	235	205	152	184	139	129	117	158	271	80	71	91	70	91	-50	386	70	81	324	500	440	256	478	804	818	164	506	572	614	161	144	186
Tax	83	51	54	45	32	41	22	24	24	36	67	17	18	16	5	11	1	65	14	19	49	80	71	44	91	135	142	31	100	92	96	21	-89	63
Net profit	300	182	182	160	121	143	119	104	94	123	202	63	53	75	65	80	-50	320	57	62	276	420	369	213	386	668	677	133	407	481	518	152	268	206
EPS ₹	16.26	9.84	9.89	8.65	6.59	7.87	6.55	5.75	5.17	6.74	11.12	3.44	2.91	4.11	3.57	4.41	-2.77	17.55	3.11	3.41	15.11	23.26	20.60	11.88	21.56	37.32	37.81	7.43	22.70	26.84	28.94	8.46	14.96	11.53
Revenue YoY	—	—	—	—	-40.6%	-8.6%	-10.6%	-13.4%	-0.2%	14.4%	65.2%	-26.3%	-27.2%	-27.2%	-53.0%	57.8%	80.1%	115.6%	14.6%	-12.1%	50.5%	28.9%	138.7%	54.0%	19.0%	19.5%	32.9%	-37.4%	14.3%	-2.5%	-0.6%	36.3%	-39.5%	-44.7%
Profit YoY	—	—	—	—	-59.7%	-21.1%	-34.8%	-34.5%	-22.1%	-14.2%	70.1%	-40.0%	-43.7%	-38.9%	-67.8%	28.2%	-195.3%	327.2%	-12.7%	-22.5%	—	31.2%	549.6%	241.4%	40.1%	59.1%	83.6%	-37.5%	5.3%	-28.1%	-23.5%	13.9%	-34.1%	-57.0%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

NATCO Pharma Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	266	293	366	467	561	622	716	1,019	1,988
Operating profit	53	56	86	117	159	187	229	279	692
Operating margin	20.0%	19.0%	23.6%	25.1%	28.3%	30.0%	31.9%	27.4%	34.8%
Other income	—	35	7	4	10	16	14	14	13
Interest	14	15	14	23	25	34	30	22	17
Depreciation	10	12	14	15	20	27	42	46	54
Profit before tax	53	61	64	83	112	141	154	225	634
Tax	11	13	12	20	34	31	1	45	139
Net profit	43	48	52	62	78	110	153	180	495

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	58	59	57	57	62	74	73	68	69	75	82	84	94	91	96	102	113	122	131	115	153	150	143	145	150	174	153	181	191	167	176	194	202	245	378	310	456	667	555	431	408	540
Operating profit	12	11	8	9	11	20	14	14	12	14	15	15	27	23	21	25	30	32	30	30	47	47	34	45	47	58	37	61	61	48	59	61	61	65	92	81	108	262	241	141	125	286
Operating margin	21.3%	18.6%	14.5%	15.3%	17.2%	26.5%	19.4%	19.9%	17.8%	19.4%	18.8%	17.7%	28.3%	25.7%	22.3%	24.8%	26.6%	26.5%	22.7%	26.2%	31.0%	31.5%	23.7%	31.1%	31.1%	33.4%	23.9%	33.4%	31.8%	28.7%	33.7%	31.2%	30.1%	26.6%	24.4%	26.1%	23.7%	39.3%	43.5%	32.6%	30.7%	53.0%
Other income	3	6	10	6	6	—	8	5	11	8	10	6	0	0	-0	1	2	0	1	2	1	6	2	4	2	1	9	1	3	7	3	3	3	6	2	5	3	6	-1	3	5	11
Interest	2	3	1	3	3	4	3	4	4	4	3	3	4	3	3	5	6	6	6	4	6	7	8	10	10	9	6	6	7	8	9	8	8	3	3	3	4	4	6	4	4	4
Depreciation	2	2	2	3	3	3	2	3	3	3	3	3	4	3	4	4	4	4	4	4	5	6	5	6	7	7	7	10	10	11	11	11	11	12	12	13	14	13	13	15	16	17
Profit before tax	12	12	22	10	13	13	17	11	17	16	17	14	19	17	14	17	22	23	21	23	31	35	23	33	32	44	33	45	47	21	42	44	45	57	78	70	93	250	221	125	110	276
Tax	2	2	10	2	1	2	5	3	4	4	3	3	4	5	-0	3	6	5	6	5	8	10	11	10	4	11	7	8	12	4	-23	10	10	13	11	19	23	53	44	27	23	59
Net profit	10	11	12	8	11	11	13	8	13	12	14	10	15	12	15	14	16	18	15	18	24	24	12	23	29	32	26	36	35	17	65	34	35	44	67	51	70	197	177	97	87	217
EPS ₹	3.66	3.83	4.35	2.74	3.99	4.02	4.50	2.87	4.68	4.30	5.09	3.71	5.23	4.41	5.17	4.89	5.69	6.19	5.00	5.84	7.61	7.79	3.74	7.25	9.15	10.14	7.96	11.01	10.52	5.02	19.63	10.25	10.35	2.50	3.86	2.92	3.96	11.29	10.13	5.58	4.98	12.33
Revenue YoY	—	—	—	—	7.3%	24.6%	29.1%	20.8%	10.2%	1.3%	11.5%	23.3%	37.5%	21.6%	18.0%	21.0%	19.8%	33.9%	35.5%	12.9%	35.2%	23.3%	9.7%	26.0%	-1.7%	15.9%	6.9%	25.3%	27.5%	-4.2%	14.8%	6.9%	5.6%	46.9%	114.8%	59.5%	125.8%	171.8%	47.0%	39.2%	-10.5%	-18.9%
Profit YoY	—	—	—	—	11.3%	5.3%	3.1%	5.1%	17.7%	7.2%	13.7%	29.4%	11.7%	2.6%	1.7%	31.9%	8.9%	43.7%	-0.2%	32.0%	48.9%	36.8%	-19.3%	25.1%	20.2%	33.0%	124.7%	60.1%	21.3%	-48.8%	147.2%	-6.4%	-0.6%	162.1%	3.4%	49.3%	101.0%	352.6%	163.4%	91.5%	25.7%	10.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 31 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	26.8%	18.5%	17.4%	15.5%	14.0%	12.2%	11.7%	13.9%	12.8%	10.7%	9.5%	6.2%	6.6%	4.0%	9.7%	8.9%	8.5%	14.7%	16.7%	21.3%	24.1%	23.7%	28.0%	27.2%	26.1%	24.8%	22.3%	17.8%	18.0%	15.4%	12.4%
ROCE	33.0%	21.8%	20.6%	18.2%	16.2%	14.4%	13.7%	16.9%	15.6%	13.5%	11.9%	7.4%	7.7%	4.7%	11.1%	11.1%	10.9%	17.4%	19.7%	24.6%	27.8%	27.2%	32.1%	32.3%	31.1%	29.4%	26.4%	21.2%	21.2%	15.4%	11.6%
Net margin	34.2%	30.8%	29.6%	27.3%	25.4%	24.1%	22.2%	22.7%	22.2%	21.5%	20.7%	17.4%	16.3%	8.7%	17.2%	16.5%	16.2%	26.4%	27.5%	31.6%	33.4%	34.7%	38.8%	42.6%	43.6%	42.6%	38.6%	35.1%	34.1%	34.8%	32.8%
EBITDA margin	42.8%	37.9%	37.5%	34.3%	31.5%	30.4%	28.3%	30.6%	30.3%	29.5%	28.7%	23.0%	21.3%	13.5%	22.7%	23.2%	24.0%	34.6%	36.1%	40.2%	41.6%	43.8%	48.1%	52.1%	50.2%	49.6%	44.6%	39.6%	40.7%	35.2%	30.2%
Debt / equity	0.06	0.11	0.11	0.11	0.11	0.08	0.08	0.08	0.08	0.06	0.06	0.06	0.06	0.09	0.09	0.02	0.02	0.03	0.03	0.05	0.05	0.06	0.06	0.03	0.03	0.04	0.04	0.03	0.03	0.08	0.08
Interest coverage	62.68	43.73	34.75	29.11	27.05	27.45	30.04	45.36	48.04	44.58	45.18	25.16	23.24	12.42	25.97	26.25	27.37	60.44	68.32	91.30	97.83	88.16	98.88	118.20	114.72	96.87	95.05	61.04	52.46	41.62	24.75
Asset turnover	0.65	0.49	0.48	0.46	0.45	0.42	0.43	0.50	0.47	0.43	0.40	0.31	0.35	0.38	0.47	0.49	0.47	0.48	0.52	0.57	0.61	0.58	0.61	0.55	0.52	0.51	0.51	0.42	0.44	0.37	0.31

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 15 periods

	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	35	35	37	36	36	36	36	36	36	36	36	36	36	36	36
Other equity / reserves	1,261	1,614	3,035	3,452	3,737	4,085	4,227	4,535	4,837	5,258	5,817	7,114	7,571	8,614	9,185
Total equity	1,296	1,649	3,072	3,489	3,774	4,122	4,264	4,571	4,874	5,294	5,853	7,150	7,607	8,650	9,221
Borrowings	98	222	173	386	316	266	404	83	165	239	363	201	273	253	706
Current liabilities	493	626	592	729	685	526	710	401	683	878	973	1,009	944	1,700	1,681
Non-current liabilities	28	38	47	83	118	143	135	106	100	82	80	79	75	76	172
Total assets	1,822	2,318	3,715	4,303	4,588	4,792	5,109	5,078	5,657	6,254	6,906	8,245	8,631	10,430	11,074
Property, plant & equipment	705	827	1,013	1,218	1,576	2,014	2,179	2,188	2,239	2,270	2,298	2,304	2,432	2,437	2,545
Capital work-in-progress	212	336	480	638	518	223	130	144	64	84	137	234	225	255	294
Investments	22	32	76	169	112	304	308	378	392	387	539	643	474	774	3,127
Inventories	357	349	438	529	558	798	762	749	743	710	700	775	766	818	908
Receivables	262	475	638	506	551	413	621	371	856	1,120	1,189	1,436	1,247	1,719	881
Cash & equivalents	24	24	22	28	20	26	111	108	132	104	70	105	120	104	199

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 11 periods

	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	112	346	464	669	417	299	46	849	1,212	1,697	1,768
Cash from investing	-176	-299	-1,116	-612	-167	-103	-5	-477	-1,033	-1,414	-2,143
Cash from financing	154	-48	651	-51	-251	-186	35	-363	-247	-211	298
Capex	175	280	424	462	359	257	243	206	359	512	391
Free cash flow	-63	66	39	207	59	42	-196	644	853	1,185	1,377
Dividends paid	26	141	181	111	154	114	82	100	171	108	90

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹2,545 cr23%

CWIP

₹294 cr3%

Investments

₹3,127 cr28%

Inventories

₹908 cr8%

Receivables

₹881 cr8%

Cash & equivalents

₹199 cr2%

Other assets

₹3,119 cr28%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
NATCO Pharma Ltd.	14,445	807.00	12.6	1.57	12.4%

StoxGud checklist: Neutral setup · 4/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-0.4%

6 months-30.1%

1 year-2.5%

3Y CAGR+2.6%

5Y CAGR-1.5%

10Y CAGR+3.3%

50-day avg₹813.74

200-day avg₹927.32

RSI (14)62

Compare NATCO Pharma Ltd. with

Cohance Lifesciences vs NATCO Pharma Poly Medicure vs NATCO Pharma Vijaya Diagnostic Centre vs NATCO Pharma NATCO Pharma vs Rainbow Childrens Medicare NATCO Pharma vs Concord Biotech

FAQs

What is the share price of NATCO Pharma Ltd.?

NATCO Pharma Ltd. (NATCOPHARM) closed at ₹807.00 on NSE on 06 Nov 2026.

What is the market cap of NATCO Pharma Ltd.?

₹14,445 crore at the latest close.

What is the P/E ratio of NATCO Pharma Ltd.?

12.6, on trailing-twelve-month earnings from its filings.

How fast is NATCO Pharma Ltd. growing?

NATCO Pharma Ltd.: revenue has compounded at 14.6% a year over three years; net profit at 25.6% a year. Latest-quarter revenue is down 44.7% year on year, profit down 57.0%.

How profitable is NATCO Pharma Ltd.?

On a trailing-twelve-month basis return on equity is 12.4%, return on capital employed 11.6%, operating margin 30.2%, net margin 32.8%.

How much debt does NATCO Pharma Ltd. have?

NATCO Pharma Ltd. is lightly geared: debt to equity is 0.08 with borrowings of ₹706 cr against cash of ₹199 cr (balance sheet of 2026-03-31). Operating profit covers interest 24.8 times.

Financials parsed from NATCO Pharma Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '16. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.